登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式(希尔记法):
C19H24N2O4S2
化学文摘社编号:
分子量:
408.53
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
InChI key
LVRLSYPNFFBYCZ-VGWMRTNUSA-N
SMILES string
S[C@H](C(N[C@@H]1C(N([C@H](C(O)=O)CCC2)[C@@]2([H])SCC1)=O)=O)CC3=CC=CC=C3
InChI
1S/C19H24N2O4S2/c22-17(15(26)11-12-5-2-1-3-6-12)20-13-9-10-27-16-8-4-7-14(19(24)25)21(16)18(13)23/h1-3,5-6,13-16,26H,4,7-11H2,(H,20,22)(H,24,25)/t13-,14-,15-,16-/m0/s1
assay
≥98% (HPLC)
form
powder
optical activity
[α]/D -70 to -85°, c = 0.5 in DMF
color
white to beige
solubility
DMSO: 20 mg/mL, clear
storage temp.
room temp
General description
Omapatrilat is a vasopeptidase dual NEP (neutral endopeptidase)/ACE (angiotensin-converting enzyme) inhibitor. It consists of a mercaptoacyl derivative of a bicyclic thazepinone dipeptide. It is used to treat heart failure.
Biochem/physiol Actions
Omapatrilat is a vasopeptidase inhibitor, a dual metalloprotease inhibitor of neutral endopeptidase (NEP, neprilysin) and angiotensin converting enzyme (ACE).
Omapatrilat is a vasopeptidase inhibitor, a dual metalloprotease inhibitor of neutral endopeptidase (NEP, neprilysin) and angiotensin converting enzyme (ACE). Omapatrilat is a highly potent antihypertensive agent, but was not approved to treat hypertension because of increased incidence of angioedema.
Features and Benefits
Omapatrilat is available through a partnership with Bristol-Myers Squibb (BMS). To learn more and view other BMS compounds, visit sigma.com/BMS.
Legal Information
Sold for research purposes only under agreement from BMS.
signalword
Warning
hcodes
Hazard Classifications
Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
target_organs
Respiratory system
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
The role of nitric oxide in heart failure (2007)
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持